Mersana Therapeutics, Inc. (MRSN)

Market Cap	44.21M
Revenue (ttm)	40.50M
Net Income (ttm)	-69.19M
Shares Out	124.63M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,470,131
Open	0.3430
Previous Close	0.3358
Day's Range	0.3430 - 0.3800
52-Week Range	0.2590 - 3.8300
Beta	1.66
Analysts	Buy
Price Target	4.00 (+1,028.03%)
Earnings Date	May 8, 2025

About MRSN

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 28, 2017
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: MRSN
• Website: https://www.mersana.com

Financial Performance

In 2024, Mersana Therapeutics's revenue was $40.50 million, an increase of 9.88% compared to the previous year's $36.86 million. Losses were -$69.19 million, -59.69% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for MRSN stock is "Buy." The 12-month stock price forecast is $4.0, which is an increase of 1,028.03% from the latest price.

Price Target

$4.0

(1,028.03% upside)

Analyst Consensus: Buy